Eyedeal and Pantheon Vision Sign Agreement to Jointly Advance Commercialization of Bioengineered Corneas
On March 27, Xi’an Eyedeal Medical Technology Co., Ltd. signed a strategic cooperation agreement with U.S.-based Pantheon Vision to jointly accelerate the production and commercialization of bioengineered corneas. The partnership aims to provide a groundbreaking treatment option for over 13 million people worldwide affected by corneal blindness.
Image source: Pantheon Vision
Guangxu Guo, Founder, Chairman, and CEO of Eyedeal, stated:”Pantheon Vision brings together a world-class ophthalmic design team. Their revolutionary approach to the development of an integrated polymer artificial cornea aims to restore vision and transform treatment options. Once commercialized, this innovative technology could fundamentally eliminate the global reliance on donated corneas and offer renewed hope for millions awaiting corneal transplants.”
Globally, more than 13 million individuals suffer from corneal blindness. The current standard treatment involves transplanting donor human corneas to replace damaged or diseased tissue. However, the shortage of donor tissue, high surgical complexity, and elevated failure rates significantly limit the accessibility of this approach.
Pantheon Vision President and CEO Dr. John Sheets previously visited Eyedeal
Dr. John Sheets Jr., President and CEO of Pantheon Vision, commented:”This collaboration represents a pivotal step forward in our mission to restore sight through bioengineered corneal solutions. We are deeply grateful for our partnership with Eyedeal Medical and are confident that our joint innovation will deliver meaningful benefits to patients suffering from corneal blindness around the world.”
Guangxu Guo concluded:”We are honored to collaborate with Pantheon Vision on this medical breakthrough by leveraging our proprietary materials and technologies. Together, we will fully utilize our complementary strengths to refine this artificial cornea solution and bring this transformative medical device to clinical use as soon as possible, helping restore vision to patients with corneal disease worldwide.”
The announcement of this collaboration has drawn significant attention from prominent global investment research firm Morningstar and leading industry media outlet Business Wire, underscoring the growing interest from investors and the ophthalmic community in cross-border innovation partnerships.
About Eyedeal Medical
Xi’an Eyedeal Medical Technology Co., Ltd. is an innovative high-tech company dedicated to the research, development, production, and global commercialization of medical-grade polymers and advanced implantable medical devices. Focusing on ophthalmology, the company is actively developing intraocular lens (IOL) products and is committed to delivering innovative medical solutions to patients around the world. Learn more: www.eyedeal.com
About Pantheon Vision
Pantheon Vision is an early-stage U.S. biotechnology company focused on developing bioengineered corneal implants to improve treatment pathways and reduce dependency on donor tissue. The company aims to deliver transformative solutions to patients in both emerging and developed markets, restoring vision and all the joy it brings. Its current pipeline is designed to improve treatment efficiency while ensuring safety, effectiveness, accessibility, and scalability. Learn more: www.pantheonvision.com